2-bromo-6-nitro-1-indanone | 66440-71-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-bromo-6-nitro-1-indanone
• 英文别名: 2-bromo-6-nitroindan-1-one；2-bromo-6-nitro-l-indanone；2-Brom-6-nitro-1-indanon；2-bromo-6-nitro-2,3-dihydroinden-1-one
• CAS: 66440-71-9
• 化学式: C₉H₆BrNO₃
• 分子量: 256.056
• InChiKey: YMAUCCABSHWVFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-6-nitro-1-indanone 在 三乙胺 作用下， 生成 6-nitroindenone
  参考文献：
  名称：

  Preparation of alkylation agents for bulged DNA microenvironments

  摘要：

  A designed molecule with capacity to alkylate DNA bulges has been prepared from readily available starting materials. The spirocyclic template utilized was designed on the basis of established architectures, and equipped with a mustard alkylating group. Preliminary studies confirm alkylation of specific bulged sequences, paving the way for second generation substrates with higher affinity.

  DOI：

  10.1016/j.bmcl.2004.03.092
• 作为产物：
  描述：

  6-硝基-1-茚满酮 在 溴 作用下， 以 溶剂黄146 为溶剂， 生成 2-bromo-6-nitro-1-indanone
  参考文献：
  名称：

  Thiazolidine derivatives

  摘要：

  具有以下结构的噻唑啉衍生物的翻译：其中取代基R.sup.1至R.sup.7的含义如下所示，并且这些衍生物在游离形式或其无毒酸盐形式具有有价值的药用特性，制备它们的方法，基于这些化合物的药物制剂以及它们作为药物的用途。

  公开号：

  US04174397A1

文献信息

• Thiazolidine derivatives
  申请人：Hoechst Aktiengesellschaft

  公开号：US04174397A1

  公开（公告）日：1979-11-13

  Thiazolidine derivatives of the formula I ##STR1## in which the substituents R.sup.1 to R.sup.7 have the meanings as indicated in the following and which have in the free form or in the form of their non toxic acid addition salts valuable pharmaceutical properties, processes for preparing them, pharmaceutical preparations on the basis of these compounds and their use as medicines.

  具有以下结构的噻唑啉衍生物的翻译：其中取代基R.sup.1至R.sup.7的含义如下所示，并且这些衍生物在游离形式或其无毒酸盐形式具有有价值的药用特性，制备它们的方法，基于这些化合物的药物制剂以及它们作为药物的用途。
• Polycyclic 2-aminodihydrothiazole systems, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06235763B1

  公开（公告）日：2001-05-22

  The invention relates to polycyclc 2-aminodihydrothiazole systems and their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I, in which the radicals have the stated meanings, and their physiologically tolerated salts and processes for their preparation are described. The compounds are suitable, for example, as anorectics.

  本发明涉及多环2-氨基二氢噻唑体系及其生理耐受盐和生理功能衍生物。描述了式I的化合物及其生理耐受盐和制备它们的方法，其中基团具有所述的含义。例如，这些化合物适用于作为压抑食欲的药物。
• Morpholine Compound
  申请人：Tanaka Yoshihito

  公开号：US20070265257A1

  公开（公告）日：2007-11-15

  A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

  化合物的化学式为(1)，其中环A是芳基，可选地具有取代基等；环B是芳烃，可选地具有取代基等；m=0-2；n=1-5；X是键等；Y是键等；Z是氢原子等或其药学上可接受的盐，其水合物或溶剂化物具有对CCR3的亲和力，并可用于治疗和/或预防免疫或炎症性疾病的药物产品。
• MORPHOLINE COMPOUND
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1801108A1

  公开（公告）日：2007-06-27

  A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

  由式（1）代表的化合物 其中，环 A 是可选具有取代基等的芳基；环 B 是可选具有取代基等的芳烯；m=0-2；n=1-5；X 是键等；Y 是键等；Z 是氢原子等，或其药学上可接受的盐、水合物或溶液对 CCR3 具有亲和力，可作为治疗和/或预防免疫性或炎症性疾病的药物产品。
• MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1801108B9

  公开（公告）日：2013-11-20